2021 Fiscal Year Final Research Report
Verify drug efficacy based on genetic information and formulate a treatment algorithm for dementia with Lewy bodies
Project/Area Number |
19K17073
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 52030:Psychiatry-related
|
Research Institution | Kansai Medical University |
Principal Investigator |
SUNADA Naotaka 関西医科大学, 医学部, 非常勤講師 (30809398)
|
Project Period (FY) |
2019-04-01 – 2022-03-31
|
Keywords | レビー小体型認知症 / 認知症を伴うパーキンソン病 / 介護者負担 / DLB / PDD / NPI-Q |
Outline of Final Research Achievements |
The regular visits required to verify the efficacy of the drug were difficult due to the spread of COVID-19 infection. Therefore, we verified the burden on caregivers using other factors. Dementia with Lewy bodies (DLB) belong to the same spectrum as Parkinson’s disease with dementia (PDD). And, in Alzheimer's disease, diabetes mellitus (DM) is associated with caregiver burden. We examined the relationship between DM and caregiver burden for DLB and PDD patients. The burden score of caregivers was higher in the DM group than in the non-DM group, but no significant difference was observed. In this study, the number of patients with type 1 DM was higher than the general prevalence, therefore, we performed an exploratory analysis. The burden score of caregivers in the type 1 DM group was higher than those in the other groups, but no significant difference was observed. In this study, factors related to caregiver burden were not clarified. We will continue to accumulate findings.
|
Free Research Field |
認知機能障害
|
Academic Significance and Societal Importance of the Research Achievements |
アルツハイマー型認知症(AD)と比較し、レビー小体型認知症(DLB)及び認知症を伴うパーキンソン病(PDD)は知見の集積が少ない。レビー小体病理は、認知症患者の剖検例で40%以上と多く認めている。バイオマーカーを重要視した診断基準から、適切な診断により、DLB及びPDDの患者数は増加が予想され、本研究の知見は学術的意義が大きいと考える。また、DLB及びPDDに対して、ADの分野でも注目されている糖尿病の因子に着眼点を置き、介護者負担を定量化し、知見の集積及び検証を行ったことは、エビデンスを構築する上で重要であり、認知症患者が地域社会で安定した生活を送る上でも社会的意義が大きいと考える。
|